{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Response Criteria', 'Evaluation of Target Lesions', 'Complete Response (CR): Disappearance of all target lesions. Any pathological', 'lymph nodes (whether target or non-target) must have reduction in short axis to', '<10 mm (<1 cm).', 'Partial Response (PR): At least a 30% decrease in the sum of the diameters of target', 'lesions, taking as reference the baseline sum diameters.', 'Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target', 'lesions, taking as reference the smallest sum on study (this includes the baseline sum if', 'that is the smallest on study). In addition to the relative increase of 20%, the sum must', 'also demonstrate an absolute increase of at least 5 mm (0.5 cm).', 'NOTE: the appearance of one or more new lesions is also considered progressions).', 'Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient', 'increase to qualify for PD, taking as reference the smallest sum diameters while on', 'study.', 'Evaluation of Non-Target Lesions', 'Complete Response (CR): Disappearance of all non-target lesions and normalization', 'of tumor marker level. All lymph nodes must be non-pathological in size (<10 mm', '[<1 cm] short axis).', 'NOTE: If tumor markers are initially above the upper normal limit, they must normalize', 'for a patient to be considered in complete clinical response.', 'Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance', 'of tumor marker level above the normal limits.', 'Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal', 'progression of existing non-target lesions. Unequivocal progression should not', 'normally trump target lesion status. It must be representative of overall disease status', 'change, not a single lesion increase.', 'Although a clear progression of \"non-target\" lesions only is exceptional, the opinion of the treating', 'physician should prevail in such circumstances, and the progression status should be confirmed at', 'a later time by the review panel (or Principal Investigator).', 'Evaluation of Overall Response Criteria', 'The best overall response is the best response recorded from the start of the treatment until', 'PD/recurrence (taking as reference for PD the smallest measurements recorded since the treatment', \"started). The patient's best response assignment will depend on the achievement of both\", 'measurement and confirmation criteria. Revised Response Evaluation Criteria in Solid Tumors', '(RECIST) Version 1.1 (Eisenhauer 2009) are summarized in the table:', 'Regeneron Pharmaceuticals, Inc.', 'Page 115 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Response According to Revised Response Evaluation Criteria in Solid Tumors', '(Version 1.1)', 'Target', 'New', 'Overall', 'Best Overall Response when', 'Lesions', 'Non-Target Lesions', 'Lesions', 'Response', 'Confirmation is Required', 'CR', 'CR', 'No', 'CR', '>4 weeks confirmation', 'CR', 'Non-CR/Non-PD', 'No', 'PR', '>4 weeks confirmation', 'CR', 'Not evaluated', 'No', 'PR', 'PR', 'Non-PD/not all evaluated', 'No', 'PR', 'SD', 'Non-PD/not all evaluated', 'No', 'SD', 'Documented at least once', '>4 weeks from baseline', 'PD', 'Any', 'Yes or No', 'PD', 'no prior SD, PR or CR', 'Any', 'PD*', 'Yes or No', 'PD', 'Any', 'Any', 'Yes', 'PD', 'CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease.', 'a In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as PD.', 'Missing Assessments and Inevaluable Designation', 'When no imaging/measurement is done at all at a particular time point, the patient is not evaluable', '(NE) at that time point. If only a subset of lesion measurements are made at an assessment, usually', 'the case is also considered NE at that time point, unless a convincing argument can be made that', 'the contribution of the individual missing lesion(s) would not change the assigned time point', 'response. This would be most likely to happen in the case of progressive disease. For example, if', 'a patient had a baseline sum of 50 mm with 3 measured lesions and at follow-up only 2 lesions', 'were assessed, but those gave a sum of 80 mm, the patient will have achieved progressive disease', 'status, regardless of the contribution of the missing lesion.', 'Best Overall Response: All Time Points', 'The best overall response is determined once all the data for the patient is known. Best response', 'determination in trials where confirmation of complete or partial response IS NOT required: Best', 'response in these trials is defined as the best response across all time points (for example, a patient', 'who has SD at first assessment, PR at second assessment, and progressive disease on last', 'assessment has a best overall response of PR). When SD is believed to be best response, it must', 'also meet the protocol specified minimum time from baseline. If the minimum time is not met', \"when SD is otherwise the best time point response, the patient's best response depends on the\", 'subsequent assessments. For example, a patient who has SD at first assessment, progressive', 'disease at second and does not meet minimum duration for SD, will have a best response of', 'progressive disease. The same patient lost to follow-up after the first SD assessment would be', 'considered inevaluable.', 'Regeneron Pharmaceuticals, Inc.', 'Page 116 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}